Top 4 Small Molecule Drug Conjugates

Published: June 2026

Small molecule drug conjugates (SMDCs) have emerged as a transformative pillar in oncology precision medicine and targeted therapeutics, enabling effective treatment of complex diseases affecting millions worldwide. These engineered molecules work by integrating highly selective targeting moieties with potent payloads, modulating key pathways, such as antigen-specific delivery, intracellular payload release, and adjacent cell penetration.

The clinical utility of SMDCs has gained significant prominence due to their ability to boost response rates, minimize off-target toxicity, extend progression-free survival, and improve quality of life. They outperform older targeted regimens across solid tumors, hematologic cancers, and other indications while overcoming limitations of traditional chemotherapies through superior tissue penetration and tunable pharmacokinetics.

To date, 22 SMDCs have either been approved or are under different stages of development. As the oncology and targeted therapeutics market expands across solid tumors, hematologic malignancies, and other indications, clinicians and healthcare facilities are actively seeking more effective, tolerable options. This rising demand presents substantial opportunities for pharmaceutical innovators to bolster pipelines, broaden indications, and drive the global evolution of precision medicine in the coming years.

Roots Analysis has conducted an exhaustive study on Next Generation Drug Conjugate Market featuring the current market landscape and future opportunities for the companies engaged in healthcare, over a span of next 9 years.

Small Molecule Drug Conjugates

Illuccix® (68Ga-PSMA-11)
Gozellix® (68Ga-PSMA-11)
TLX101-CDx, Pixclara® (18F-floretyrosine)
AST-3424

Next Generation Drug Conjugate Small Molecule

Interested in exploring all 320+ next generation drug conjugates, along with their recent initiatives?

Discover Below the Details on Small Molecule Drug Conjugates

Let us dive deep into the details of the small molecule drug conjugates. It is essential to note that the selection of SMDCs can differ substantially according to the defined criteria.

1. Illuccix® (68Ga-PSMA-11)

The section provides information on the various parameters, with details on list of developer, mechanism of action, route of administration, type of therapy, target patient population, and target indication.

Developer: Telix Pharmaceuticals
Mechanism of Action: Radiation Induced Cytotoxicity
Route of Administration: Intravenous
Type of Therapy: Monotherapy
Target Patient Population: Adult
Target Indication: Prostate Cancer

Recent Developments

In January 2026, Telix announced that China’s NMPA has accepted the New Drug Application for Illuccix, 68Ga-PSMA-11 prostate cancer imaging agent, marking the company’s first regulatory filing in Greater China with Grand Pharmaceutical Group.

To know more about the recent initiatives of Illuccix® (68Ga-PSMA-11) and other small molecule drug conjugates, access full report.

2. Gozellix® (68Ga-PSMA-11)

Developer: Telix Pharmaceuticals
Mechanism of Action: Radiation Induced Cytotoxicity
Route of Administration: Intravenous
Type of Therapy: Monotherapy
Target Patient Population: Adult
Target Indication: Prostate Cancer

Recent Developments

In January 2026, researchers initiated the BiPASS trial to evaluate Gozellix and Illuccix for prostate cancer detection. While both are already approved as diagnostic agents, this study focuses on their combined use with MRI to enhance diagnostic accuracy for challenging lesions and minimize the necessity for invasive biopsies. By leveraging Gozellix’s high-affinity binding, the trial aims to demonstrate how these advanced molecular tools can refine clinical decision-making and improve patient outcomes.

To know more about the recent initiatives of Gozellix® (68Ga-PSMA-11) and other small molecule drug conjugates, access full report.

3. TLX101-CDx, Pixclara®3 (18F-floretyrosine)

Developer: Telix Pharmaceuticals
Mechanism of Action: Radiation Induced Cytotoxicity
Route of Administration: Intravenous
Type of Therapy: Monotherapy
Target Patient Population: Child, Adult, Older Adult
Target Indication: Glioblastoma

Recent Developments

In April 2026, Telix announced that the FDA has accepted the resubmitted New Drug Application for TLX101 Px (Pixclara®), an experimental 18F FET PET imaging agent for glioma.

To know more about the recent initiatives of TLX101-CDx, Pixclara®3 and other small molecule drug conjugates, access full report.

4. AST-3424

Developer: Shenzhen Ascentawits Pharmaceuticals
Mechanism of Action: Drug Induced Cytotoxicity
Route of Administration: Intravenous
Type of Therapy: Monotherapy
Target Patient Population: Adult, Older Adult
Target Indication: Hepatocellular Carcinoma

Recent Developments

In September 2025, Haisco Pharmaceuticals secured exclusive rights from Shenzhen Ascentawits to develop and commercialize the SMC drug AST-3424 in mainland China, Hong Kong, and Macau.

To know more about the recent initiatives of AST-3424 and other small molecule drug conjugates, access full report.

What About Other SMDCs Around the World?

The above article features the small molecule drug conjugates selected from a pool of around 320 next generation drug conjugates that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources: